FranceFrance

Nicox glaucoma drug meets endpoints in Phase IIb study

14.03.2012

Sophia Antipolis/ Madison – French NicOx S.A. and the global eye health specialist Bausch & Lomb have announced positive top-line results from their phase 2b dose finding study with BOL-303259-X, a nitric oxide-donating version of Pfizer’s prostaglandin F2-alpha analogue latanoprost, in 400 patients with open-angle glaucoma or ocular hypertension. As shown in two previous Phase II trials conducted during NiCox’s partnership with Pfizer, which ran from 2004-2009, BOL-303259-X (previously NCX 116, PF-3187207) was superior to Pfizer’s lipophilic prostaglandin F2-alpha formulation latanoprost (Xalatan®). In 2 of 4 dose regimes, the NO-donating drug lowered intraocular pressure (IOP) better than Xalatan. On top of that, the responder rate was 68.7% for the most efficacious dose of BOL-303259-X, compared to 47.5% for Xalatan®. The most frequent side effect was reddening of the eyes (hyperemia). The results triggered a US-$10m milestone from Bausch & Lomb to its French partner. The US eye specialist announced it will initiate a global phase 3 development program for the eye drops. The firms believe that NO improves the IOP lowering effect of prostaglandin F2-alpha. In two Phase II trials completed in 2008, the drug was reported to be at least 20% more effective than Xalatan®, according to Pfizer, which re-licensed all development and commercialisation rights to NiCox in August 2009 after having refocused its drug development priorities.

Politics / Law

06.03.2012

The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Tech Review

06.03.2012

The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review

06.03.2012

Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review

06.03.2012

Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review

06.03.2012

The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial

02.03.2012

Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial

01.03.2012

Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Displaying results 21 to 30 out of 1983

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/2/article/nicox-glaucoma-drug-meets-endpoints-in-phase-iib-study.html

Product of the week

Products

Events

All Events

Current issue

All issues